CAN URINE BOUND DIAGNOSTIC TESTS REPLACE CYSTOSCOPY IN THE MANAGEMENT OF BLADDER CANCER?

Abstract

No AccessJournal of UrologyClinical Urology: Original Articles1 Jun 1998CAN URINE BOUND DIAGNOSTIC TESTS REPLACE CYSTOSCOPY IN THE MANAGEMENT OF BLADDER CANCER? H.G. WIENER, CH. MIAN, A. HAITEL, A. PYCHA, G. SCHATZL, and M. MARBERGER H.G. WIENERH.G. WIENER , CH. MIANCH. MIAN , A. HAITELA. HAITEL , A. PYCHAA. PYCHA , G. SCHATZLG. SCHATZL , and M. MARBERGERM. MARBERGER View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)63184-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compare the diagnostic value of NMP22 [dagger] and BTA stat [double dagger] testing, and QUANTICYT [section] computer assisted dual parameter image analysis to cytology and cystoscopy in patients who had symptoms suggestive of transitional cell cancer or were being followed after treatment for that disease. [dagger] Matritech, Inc., Newton, Massachusetts. [double dagger] Bard Diagnostics, Redmond, Washington. [section] Gentian Scientific Software, Niawier, The Netherlands. Materials and Methods: We prospectively evaluated voided urine and/or barbotage specimens from 291 patients a mean of 65.2 years old. All voided urine samples were evaluated by quick staining and standard cytology, the BTA stat 1-step qualitative assay (which detects a bladder tumor associated antigen) and the NMP22 test (which detects a nuclear mitotic apparatus protein). In addition, barbotage specimens were evaluated by QUANTICYT computer assisted dual parameter image analysis. All patients underwent subsequent cystoscopy and biopsy evaluation of any suspicious lesion. Sensitivity, specificity, and the predictive value of positive and negative results were determined in correlation with endoscopic and histological findings. Results: In 91 patients with histologically proved transitional cell carcinoma overall sensitivity was 48, 57, 58, 59 and 59% for the NMP22 test, the BTA stat test, rapid staining cytology of barbotage samples, rapid staining cytology of voided urine specimens and image analysis, respectively. For histological grades 1 to 3 underlying transitional cell carcinoma sensitivity was 17, 61 and 90% for urinary cytology, 48, 58 and 63% for the BTA stat test, and 52, 45 and 50% for the NMP22 test, respectively. Specificity was 100% for cytology, 93% for image analysis, 70% for the NMP22 test and 68% for the BTA stat test. Conclusions: Immunological markers are superior to cytological evaluation and image analysis for detecting low grade transitional cell carcinoma but they have low specificity and sensitivity in grade 3 transitional cell carcinoma. Urine bound diagnostic tools cannot replace cystoscopy. References 1 : Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol.1993; 37: 163. Google Scholar 2 : Biology and management of bladder cancer. New Engl. J. Med.1990; 322: 1129. Google Scholar 3 : Morphometric grading of bladder tumors in comparison with histologic grading by pathologists. Hum. Path.1983; 144: 140. Google Scholar 4 : Critical appraisal of tumor markers in bladder cancer. Sem. Urol.1993; 11: 145. Google Scholar 5 : Quanticyt: karyometric analysis of bladder washings for patients with superficial bladder cancer. Urology1996; 48: 357. Google Scholar 6 : Histological Typing of Urinary Bladder Tumors. In: . Geneva: World Health Organization1973. Google Scholar 7 : 4th ed. Union Internationale Contre le Cancer. In: . Geneva: International Union Against Cancer1987. Google Scholar 8 : Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family. J. Urol., part 21997; 157: 28A. abstract 110. Google Scholar 9 : Clinical evaluation of nuclear matrix protein (NMP22) in urine as a novel marker for urothelial cancer. Eur. Urol.1997; 31: 163. Google Scholar 10 : Soluble forms of the adhesion E-cadherin molecule in urine. J. Clin. Path.1995; 48: 179. Google Scholar 11 : Detection of bladder carcinoma: a urine test, based on cytokeratin expression. J. Urol., part 21997; 157: 339A. abstract 1326. Google Scholar 12 : Detection of human bladder cancer cells in voided urine samples by assaying for the presence of telomerase activity. J. Urol., part 21997; 157: 338A. abstract 1321. Google Scholar 13 : Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol.1995; 154: 379. Link, Google Scholar 14 : Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J. Urol.1996; 155: 475. Link, Google Scholar 15 : Results of a European multicenter trial comparing the BTA-stat test to urine cytology in patients suspected of having bladder cancer. J. Urol., part 21997; 157: 337A. abstract 1316. Google Scholar 16 : Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. J. Urol., part 21997; 157: 337A. abstract 1318. Google Scholar 17 : Detection of recurrent bladder cancer using a new quantitative assay for bladder tumor. J. Urol., part 21997; 157: 337A. abstract 1317. Google Scholar 18 : Editorial comment. J. Urol.1995; 154: 383. Google Scholar 19 : Evaluation of the NMP22 immunoassay in the detection of transitional cell carcinoma (TCC) of the urinary tract. J. Urol., part 21997; 157: 336A. abstract 1314. Google Scholar 20 : Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol.1996; 156: 363. Link, Google Scholar From the Departments of Urology and Pathology, University of Vienna, Vienna, Austria© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySCHMIDBAUER J, WITJES F, SCHMELLER N, DONAT R, SUSANI M and MARBERGER M (2018) Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence CystoscopyJournal of Urology, VOL. 171, NO. 1, (135-138), Online publication date: 1-Jan-2004.PFISTER C, CHAUTARD D, DEVONEC M, PERRIN P, CHOPIN D, RISCHMANN P, BOUCHOT O, BEURTON D, COULANGE C and RAMBEAUD J (2018) Immunocyt Test Improves the Diagnostic Accuracy of Urinary Cytology: Results of a French Multicenter StudyJournal of Urology, VOL. 169, NO. 3, (921-924), Online publication date: 1-Mar-2003.BOMAN H, HEDELIN H, JACOBSSON S and HOLMÄNG S (2018) Newly Diagnosed Bladder Cancer: The Relationship of Initial Symptoms, Degree of Microhematuria and Tumor Marker StatusJournal of Urology, VOL. 168, NO. 5, (1955-1959), Online publication date: 1-Nov-2002.Eissa S, Swellam M, Sadek M, Mourad M, Ahmady O and Khalifa A (2018) Comparative Evaluation of the Nuclear Matrix Protein, Fibronectin, Urinary Bladder Cancer Antigen and Voided Urine Cytology in the Detection of Bladder TumorsJournal of Urology, VOL. 168, NO. 2, (465-469), Online publication date: 1-Aug-2002.BOMAN H, HEDELIN H and HOLMäNG S (2018) FOUR BLADDER TUMOR MARKERS HAVE A DISAPPOINTINGLY LOW SENSITIVITY FOR SMALL SIZE AND LOW GRADE RECURRENCEJournal of Urology, VOL. 167, NO. 1, (80-83), Online publication date: 1-Jan-2002.PONSKY L, SHARMA S, PANDRANGI L, KEDIA S, NELSON D, AGARWAL A and ZIPPE C (2018) SCREENING AND MONITORING FOR BLADDER CANCER: REFINING THE USE OF NMP22Journal of Urology, VOL. 166, NO. 1, (75-78), Online publication date: 1-Jul-2001.SÁNCHEZ-CARBAYO M, URRUTIA M, SILVA J, ROMANÍ R, DE BUITRAGO J and NAVAJO J (2018) COMPARATIVE PREDICTIVE VALUES OF URINARY CYTOLOGY, URINARY BLADDER CANCER ANTIGEN, CYFRA 21-1 AND NMP22 FOR EVALUATING SYMPTOMATIC PATIENTS AT RISK FOR BLADDER CANCERJournal of Urology, VOL. 165, NO. 5, (1462-1467), Online publication date: 1-May-2001.LOKESHWAR V and SOLOWAY M (2018) CURRENT BLADDER TUMOR TESTS: DOES THEIR PROJECTED UTILITY FULFILL CLINICAL NECESSITY?Journal of Urology, VOL. 165, NO. 4, (1067-1077), Online publication date: 1-Apr-2001.KONETY B and GETZENBERG R (2018) URINE BASED MARKERS OF UROLOGICAL MALIGNANCYJournal of Urology, VOL. 165, NO. 2, (600-611), Online publication date: 1-Feb-2001.CASELLA R, HUBER P, BLÖCHLINGER A, STOFFEL F, DALQUEN P, GASSER T and LEHMANN K (2018) URINARY LEVEL OF NUCLEAR MATRIX PROTEIN 22 IN THE DIAGNOSIS OF BLADDER CANCER: : EXPERIENCE WITH 130 PATIENTS WITH BIOPSY CONFIRMED TUMORJournal of Urology, VOL. 164, NO. 6, (1926-1928), Online publication date: 1-Dec-2000.HALLING K, KING W, SOKOLOVA I, MEYER R, BURKHARDT H, HALLING A, CHEVILLE J, SEBO T, RAMAKUMAR S, STEWART C, PANKRATZ S, O'KANE D, SEELIG S, LIEBER M and JENKINS R (2018) A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, VOL. 164, NO. 5, (1768-1775), Online publication date: 1-Nov-2000.SCHNEEWEISS S, KRIEGMAIR M and STEPP H (2018) IS EVERYTHING ALL RIGHT IF NOTHING SEEMS WRONG? A SIMPLE METHOD OF ASSESSING THE DIAGNOSTIC VALUE OF ENDOSCOPIC PROCEDURES WHEN A GOLD STANDARD IS ABSENTJournal of Urology, VOL. 161, NO. 4, (1116-1119), Online publication date: 1-Apr-1999.Elhilali M (2018) EDITORIAL: THE POTENTIAL USEFULNESS OF BLADDER CANCER MARKERSJournal of Urology, VOL. 161, NO. 3, (810-811), Online publication date: 1-Mar-1999.Casella R, Lehmann K and Gasser T (2018) RE: NMP22 IS A SENSITIVE, COST-EFFECTIVE TEST IN PATIENTS AT RISK FOR BLADDER CANCERJournal of Urology, VOL. 162, NO. 2, (500-501), Online publication date: 1-Aug-1999.MIAN C, PYCHA A, WIENER H, HAITEL A, LODDE M and MARBERGER M (2018) IMMUNOCYT1: A NEW TOOL FOR DETECTING TRANSITIONAL CELL CANCER OF THE URINARY TRACTJournal of Urology, VOL. 161, NO. 5, (1486-1489), Online publication date: 1-May-1999. Volume 159Issue 6June 1998Page: 1876-1880 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information H.G. WIENER More articles by this author CH. MIAN More articles by this author A. HAITEL More articles by this author A. PYCHA More articles by this author G. SCHATZL More articles by this author M. MARBERGER More articles by this author Expand All Advertisement PDF downloadLoading ...